文献速递类风湿关节炎

活动性类风湿关节炎患者多次转换阿达木单抗生物类似药PF-06410293与参照阿达木单抗:一项3期、开放标签、随机、平行组研究

Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study.
PubMed 文献 · Lancet Rheumatol · 2023-08-21

这项3期开放标签随机平行组研究在10个国家61个中心纳入445例活动性类风湿关节炎患者,比较多次转换参照阿达木单抗与生物类似药adalimumab-afzb(转换组)与持续使用参照阿达木单抗(非转换组)的药代动力学和安全性。药代动力学人群(n=380)中AUCτ和Cmax的几何均值比及90%CI均在预设等效界值80-125%内,两组严重不良事件比例无显著差异,提示多次转换在药代动力学(作为疗效替代指标)和安全性方面风险不高于单用参照阿达木单抗。

要点

  • 转换组与非转换组AUCτ几何均值比105.31(90%CI 89.16-124.39),Cmax几何均值比102.56(90%CI 89.78-117.17),均在80-125%等效界值内。
  • 转换组严重不良事件3例(1%)vs非转换组8例(4%),因不良事件停药转换组8例(4%)vs非转换组9例(4%),无死亡报告。
  • 作者结论认为多次转换在药代动力学(作为疗效替代指标)或安全性方面的风险不高于单用参照阿达木单抗。

核心结论

  • 在活动性类风湿关节炎患者中,参照阿达木单抗与adalimumab-afzb之间多次转换在药代动力学(作为疗效替代指标)或安全性方面的风险不高于单用参照阿达木单抗。

研究设计与样本

  • 开放标签、随机、平行组3期研究,在10个国家61个中心(社区29个、医院12个、学术20个)开展,纳入445例患者,427例完成前10周后随机分配(转换组213例,非转换组214例)。
  • 入组患者年龄18-70岁,符合2010年美国风湿病学会-欧洲抗风湿病联盟类风湿关节炎分类标准至少4个月,基于医师评估为中度至重度活动性类风湿关节炎,且已接受甲氨蝶呤至少12周、首次研究药物给药前稳定剂量至少4周。
  • 所有患者先接受皮下参照阿达木单抗(40 mg/0.4 mL [100 mg/mL])每2周一次治疗10周,第10周按1:1随机分配至转换组(参照阿达木单抗与adalimumab-afzb [40 mg/0.8 mL (50 mg/mL)] 每2周一次之间转换三次)或非转换组(持续皮下参照阿达木单抗40 mg/0.4 mL [100 mg/mL] 每2周一次),按体重组分层,患者、研究者和中心人员对治疗分配非盲。
  • 主要终点为药代动力学人群第30-32周的最大观察血清浓度(Cmax)和血浆浓度-时间曲线下面积(AUCτ),互换性基于几何均值比及相应90%CI在预设等效界值80-125%内。
  • 安全性在所有至少接受一剂adalimumab-afzb或参照阿达木单抗的患者中分析,试验注册号ClinicalTrials.gov NCT04230213。

主要发现

  • 药代动力学人群(n=380)中,转换组几何均值AUC为2237 μg×h/mL,非转换组为2125 μg×h/mL;转换组Cmax为8.21 μg/mL,非转换组为8.00 μg/mL,两组平均稳态药代动力学参数未见临床意义差异。
  • AUCτ几何均值比105.31(90%CI 89.16-124.39),Cmax几何均值比102.56(90%CI 89.78-117.17),均在预设等效界值内。
  • 严重不良事件转换组3例(1%)vs非转换组8例(4%),特别关注的不良事件中3级或以上、因不良事件停药(转换组8例[4%] vs 非转换组9例[4%])、抗药抗体阳性患者中的免疫原性反应均未见有意义差异,研究期间无死亡报告。
  • 参与者中位年龄56岁(IQR 46-63),女性354例(83%)、男性73例(17%),422例(99%)为白人。

关键数值与推荐

  • 互换性判定标准:AUCτ和Cmax的几何均值比及相应90%CI均在预设等效界值80-125%内;AUCτ几何均值比105.31(90%CI 89.16-124.39),Cmax几何均值比102.56(90%CI 89.78-117.17),均满足。
  • 入组标准:年龄18-70岁,符合2010年美国风湿病学会-欧洲抗风湿病联盟类风湿关节炎分类标准至少4个月,基于医师评估为中度至重度活动性类风湿关节炎,已接受甲氨蝶呤至少12周且首次给药前稳定剂量至少4周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An adalimumab biosimilar with an interchangeability designation could increase access to effective treatment for more patients. We aimed to assess the interchangeability of adalimumab biosimilar PF-06410293 (adalimumab-afzb) and reference adalimumab using a multi-switch study design. METHODS: We did an open-label, randomised, parallel-group study at 61 community (n=29), hospital (n=12), and academic (n=20) sites in ten countries (Bulgaria, Bosnia and Herzegovina, Czech Republic, Lithuania, Poland, Russia, Serbia, South Africa, Ukraine, and USA). Eligible patients were aged 18-70 years and met the 2010 American College of Rheumatology-European League Against Rheumatism classification criteria for rheumatoid arthritis for at least 4 months with moderately to severely active rheumatoid arthritis, based on their physician's evaluation. Eligible patients had been receiving methotrexate for at least 12 weeks and been on a stable dose for at least 4 weeks before the first dose of study medication. All patients received subcutaneous reference adalimumab (40 mg/0·4 mL [100 mg/mL] every 2 weeks) for 10 weeks before randomisation. At week 10, patients were randomly assigned (1:1) to either three switches between subcutaneous reference adalimumab (40 mg/0·4 mL [100 mg/mL] every 2 weeks) and adalimumab-afzb (40 mg/0·8 mL [50 mg/mL] every 2 weeks; switching group), or continuous dosing with subcutanous reference adalimumab (40 mg/0·4 mL [100 mg/mL] every 2 weeks; non-switching group) with stratification by bodyweight groups. Patients, investigators, and site personnel were not masked to treatment allocation. Primary endpoints were maximum observed serum concentration (Cmax) and area under plasma concentration-time curve (AUCτ) during weeks 30-32 in the pharmacokinetic population. Interchangeability was based on geometric mean ratios and corresponding 90% CIs within prespecified equivalence margins of 80-125% for both primary endpoints. Safety was analysed in all patients who received at least one dose of adalimumab-afzb or reference adalimumab. This trial is registered with ClinicalTrials.gov, NCT04230213. FINDINGS: Of the 569 patients assessed for eligibility between Jan 13, 2020, and June 22, 2021, 445 were enrolled, and 427 completed the first 10 weeks and were randomly assigned (213 to the switching group and 214 to the non-switching group). Participants had a median age of 56 years (IQR 46-63), 354 (83%) of 427 patients were women and 73 (17%) were men, and 422 (99%) were White. In the pharmacokinetic population (n=380), no clinically meaningful differences were observed in mean steady-state pharmacokinetic parameters between the switching and non-switching groups (geometric mean AUC 2237 μg × h/mL in the switching group and 2125 μg × h/mL in the non-switching group; Cmax 8·21 μg/mL in the switching group and 8·00 μg/mL in the non-switching group). Geometric mean ratios and 90% CIs for AUCτ (105·31, 89·16-124·39) and Cmax (102·56, 89·78-117·17) were within prespecified equivalence margins. No meaningful differences were observed in the proportion of patients who had serious adverse events (three [1%] of 213 patients in the switching group vs eight [4%] of 214 patients in the non-switching group), grade 3 or higher adverse events of special interest, discontinuations due to adverse events (eight [4%] vs nine [4%]), or immunogenic reactions in antidrug antibody-positive patients. No deaths were reported during the study. INTERPRETATION: The risk of multiple switches between reference adalimumab and adalimumab-afzb with respect to diminished efficacy (using pharmacokinetics as a surrogate) or safety is not greater than the risk of using reference adalimumab alone. FUNDING: Pfizer. VIDEO ABSTRACT.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Fleischmann RM, Saikali W, Lakhanpal S, et al. Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study. Lancet Rheumatol. 2023. PMID: 38251497. doi:10.1016/S2665-9913(23)00161-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。